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Abstract: To date, anti-tumor necrosis factor alfa (anti-TNF-α) therapy is the only alternative 
to nonsteroidal anti-inflammatory drugs for the treatment of ankylosing spondylitis. Etanercept 
is a soluble TNF receptor, with a mode of action and pharmacokinetics different to those of 
antibodies and distinctive efficacy and safety. Etanercept has demonstrated efficacy in the treat-
ment of ankylosing spondylitis, with or without radiographic sacroiliitis, and other manifesta-
tions of the disease, including peripheral arthritis, enthesitis, and psoriasis. Etanercept is not 
efficacious in inflammatory bowel disease, and its efficacy in the treatment of uveitis appears 
to be lower than that of other anti-TNF drugs. Studies of etanercept confirmed regression of 
bone edema on magnetic resonance imaging of the spine and sacroiliac joint, but failed to 
reduce radiographic progression, as do the other anti-TNF drugs. It seems that a proportion 
of patients remain in disease remission when the etanercept dose is reduced or administration 
intervals are extended. Etanercept is generally well tolerated with an acceptable safety profile 
in the treatment of ankylosing spondylitis. The most common adverse effect of etanercept treat-
ment is injection site reactions, which are generally self-limiting. Reactivation of tuberculosis, 
reactivation of hepatitis B virus infection, congestive heart failure, demyelinating neurologic 
disorders, hematologic disorders like aplastic anemia and pancytopenia, vasculitis, immuno-
genicity, and exacerbation or induction of psoriasis are class effects of all the anti-TNF drugs, 
and have been seen in patients with ankylosing spondylitis. However, etanercept is less likely 
to induce reactivation of tuberculosis than the other anti-TNF drugs and it has been suggested 
that etanercept might be less immunogenic, especially in ankylosing spondylitis. Acute uveitis, 
Crohn’s disease, and sarcoidosis are other adverse events that have been rarely associated with 
etanercept therapy in patients with ankylosing spondylitis.
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Introduction
Spondyloarthritis refers to a heterogeneous group of diseases that share clinical, 
pathogenic, and hereditary features, and include ankylosing spondylitis (AS) and 
psoriatic arthritis. The spondyloarthritides are characterized by chronic inflamma-
tion of the enthesis with a tendency to bone ankylosis. The most frequent clinical 
features are sacroiliitis, enthesitis, iritis, oligoarthritis, psoriasis, and inflammatory 
bowel disease.1
The prevalence of spondyloarthropathy is estimated to be between 0.1% and 2.5%, 
although figures vary from one study to another. The reported incidence ranges from 
0.3 to 7.3/100,000 inhabitants per year.2 The impact on quality of life can be very 
negative, given that pain and functional disability affect patients both physically and 
psychologically.
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Nonsteroidal anti-inflammatory drugs and physical 
exercise have been the cornerstone of treatment for spon-
dyloarthritis, but are not effective in some cases. Other 
disease-modifying antirheumatic drugs (DMARDs) like sul-
fasalazine, methotrexate, or leflunomide, are recommended 
for treating peripheral arthritis or extra-articular features. 
However, in cases of exclusive spinal involvement that do 
not respond to nonsteroidal anti-inflammatory drugs, the 
only option to date is to use anti-tumor necrosis factor (TNF) 
drugs. Since the advent of anti-TNF drugs, the symptoms of 
spondyloarthritis have improved dramatically. Further, their 
use has been linked to the clearing of active lesions on mag-
netic resonance imaging (MRI), such as bone edema, but the 
studies published to date have not demonstrated prevention 
of structural damage.3
The primary target of treatment is remission of the disease 
and, when that fails, to minimize inflammatory activity, to 
improve the signs and symptoms of spondyloarthritis, and to 
prevent structural damage and functional disability, thus safe-
guarding the patient’s quality of life. Therefore, persistence of 
activity indicates the need for a change of treatment.
The Assessment of Spondyloarthritis International 
Society (ASAS) recommends use of anti-TNF in patients 
diagnosed with AS or spondyloarthritis if they have active 
disease and have not improved with conventional treatment.4 
Currently, there are four anti-TNF agents approved for 
spondyloarthritis, including three monoclonal antibodies, ie, 
infliximab, adalimumab, and golimumab, and a soluble TNF 
receptor, etanercept. All four have efficacy demonstrated in 
randomized clinical trials, with significant superiority over 
placebo and about 60% of patients reaching an ASAS 20 
response versus 20% of patients assigned to placebo.
Etanercept is composed of two recombinant forms of the 
human TNF receptor P75 fused to an Fc portion of human 
immunoglobulin G1, and is administered subcutaneously 50 mg 
a week or 25 mg twice a week. It has a differences regarding 
way of action and pharmacokinetics, what implies differences 
with antibodies in effectiveness and safety.
In this paper, we review the efficacy and safety of etan-
ercept in the treatment of AS, and how it differs from the 
other anti-TNF drugs reported in the literature.
Efficacy of etanercept in ankylosing 
spondylitis
Efficacy outcome measures used  
in the studies
Disease activity in patients with AS has been evaluated using 
the Bath Ankylosing Spondylitis Disease Activity Index5 
(BASDAI), physical function using the Bath Ankylosing 
Spondylitis Functional Index6 (BASFI), and mobility by the 
Bath Ankylosing Spondylitis Metrology Index7 (BASMI).
In 2001, the ASAS developed outcome measures recom-
mended for use in trials of symptom-modifying therapy.8 The 
ASAS 20 improvement criteria summarize changes in the 
domains of physical function, pain, patient global assessment, 
and inflammation. A positive response is defined as a 20% or 
greater improvement and a net improvement of one unit on 
a 10-unit scale in each of three domains, with no worsening 
in the fourth. An ASAS 40 response is defined as $40% 
improvement of at least two units in each of three domains, 
with no worsening in the fourth. ASAS partial remission is 
defined as a score below two units in each domain, and ASAS 
5/6 is defined as 20% improvement in five of six domains, 
adding C-reactive protein and lateral vertebral flexion.
More recently, the ASAS association has validated 
the Ankylosing Spondylitis Disease Activity Score,9 that 
includes C-reactive protein levels in addition to some of the 
BASDAI questions and is a highly discriminatory instrument 
for assessing disease activity in AS.
Efficacy in ankylosing spondylitis
The efficacy of etanercept in AS has been assessed in several 
randomized clinical trials (Table 1). The first to evaluate 
the efficacy of etanercept in AS was published in 2002, 
with 40 active AS patients randomly assigned to receive 
etanercept 25 mg twice weekly or placebo for 4 months.10 
The intention-to-treat analysis revealed an ASAS 20 rate of 
80% in the etanercept group versus 30% in the placebo group 
(P = 0.004). Significant improvement was achieved in four 
of the five measures of ASAS 20. The treatment arm also 
showed significantly greater improvement in many of the 
secondary outcome measures (physician’s global assessment 
of disease activity, chest expansion, erythrocyte sedimenta-
tion rate, and C-reactive protein level). Patients in the placebo 
group were treated with etanercept in a 6-month, open-label 
extension of the trial, with a rapid response and no statisti-
cally significant differences in efficacy from patients treated 
with etanercept throughout the entire 10-month period.11
In June 2003, a multicenter randomized clinical trial 
including 30 patients with active AS was published.12 In the 
first phase of the study, patients were randomized to receive 
either etanercept 25 mg twice weekly (n = 14) or placebo 
(n = 16) for 6 weeks. Nonsteroidal anti-inflammatory drugs 
were permitted, but steroids and DMARDs had to be stopped 
prior to the study. The primary outcome parameter (.50% 
improvement on BASDAI) was achieved by 57% of the 
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Table 1 Main randomized clinical trials analyzing the efficacy of etanercept in ankylosing spondyloarthritis
Reference Year Type n Duration (weeks) Endpoints P
Gorman et al10
Davis et al11
2002 RCT
OLe
20/20
17
16
40
ASAS 20 0.004
Brandt et al12,13 2003 RCT
OLe
14/16
23
6
54
BASDAi 50, ASAS 20, BASDAi,  
BASFi, BASMi
0.004
Davis et al14,15 2003 RCT
OLe
138/139
128*
24
192
ASAS 20 0.0001
Calin et al16
Dijkmans et al17
2004 RCT
OLe
45/39
43
12
96
ASAS 20, 40, 5/6, BASDAi 0.001
van der Heijde et al18 2006 RCT 305/51 12 ASAS 20, 40, 5/6 0.001
Braun et al19 2007 RCT 305/51 12 BASFi, euroQOL-5D, SF-36 0.001
Braun et al20 2011 RCT 379/187 16 ASAS 20, 40, 5/6, BASDAi,  
BASFi, BASMi
0.0001
Li et al21 2013 MeT 1,570 - ASAS 20, 40, 5/6, partial remission,  
BASFi, BASDAi, BASMi
0.00001
Note: *includes only patients receiving eTN from the beginning of the study.
Abbreviations: ASAS, Assessment of Spondyloarthritis international Society; eTN, etanercept; MeT, meta-analysis; OLe, open-label extensions; RCT, randomized clinical 
trial; BASFi, Ankylosing Spondylitis Functional index; BASDAi, Bath Ankylosing Spondylitis Disease Activity index; BASMi, Bath Ankylosing Spondylitis Metrology index.
etanercept group versus 6% of the placebo group (P = 0.004). 
An ASAS 20 response was achieved by 78.6% versus 25% 
of patients, respectively. Similarly, pain, physical function, 
mobility, quality of life, and scores on BASDAI, BASFI, and 
BASMI improved significantly. In the second phase of the 
study, both groups (placebo and etanercept) were treated with 
etanercept for 12 weeks, and 56% of patients in the placebo 
group achieved a .50% improvement in BASDAI score. 
After 12 weeks of treatment, all patients discontinued etaner-
cept, and 75% experienced a relapse in a mean of 27 weeks. 
These patients were eligible to restart etanercept in a 54-week, 
open-label extension trial.13 The intention-to-treat analysis 
showed that 57.7% of patients achieved a 50% improvement 
in the BASDAI, and 73.1% were responders using the ASAS 
20 criteria. This confirms that readministration of etanercept 
is efficacious and safe in AS patients.
Another multicenter randomized clinical trial in 2003 
assessed the efficacy of etanercept in 277 AS patients.14 In 
the first 24-week, double-blind trial, patients were random-
ized to receive etanercept 25 mg or placebo twice weekly. 
The primary outcome measure, ASAS 20, was achieved by 
59% of patients in the active treatment group and by 28% 
of patients in the placebo group at week 12, and by 57% and 
22% patients, respectively, at week 24, with a statistically 
significant difference between the groups. ASAS 50 and 
70 responses were achieved in 40% and 20% of etanercept 
patients, respectively. In an open-label extension of this 
study, 257 patients received etanercept for 168 weeks.15 The 
patients who had received etanercept in the double-blind trial 
had a sustained response, with 71% achieving an ASAS 20 
at week 96 and 81% at week 192. Patients who switched to 
etanercept in the open-label extension had similar responses, 
with 70% attaining an ASAS 20 at week 24, 78% at week 
72, and 82% at week 168.
In 2004, another multicenter randomized clinical trial 
was performed in Europe, with 45 patients randomly 
assigned to etanercept 25 mg and 39 to placebo twice 
weekly for 12 weeks.16 Significantly more patients were 
ASAS 20 responders in the etanercept group (60% versus 
23%, respectively). ASAS 50 and ASAS 70 responses were 
achieved by 49% and 24% of patients in the etanercept 
group, respectively. Simultaneous significant improvement of 
functional status and metrology were observed. A 96-week, 
open-label extension of this study with 81 patients confirmed 
the improvement, with 83% of ASAS 20 responders in the 
etanercept/etanercept group and 74% in the placebo/etaner-
cept group.17
In 2006, a 12-week randomized clinical trial compared 
the efficacy of etanercept 50 mg once weekly with that of 
etanercept 25 mg twice weekly and placebo in 365 patients 
with AS.18 Similar discontinuation rates were found between 
the etanercept groups. ASAS 20 response rates were higher 
in patients on etanercept compared with those on placebo 
(74.2%, 71.3%, and 37.3%, respectively, P = 0.001). Similar 
results were found when analyzing ASAS 5/6, ASAS 40, and 
other measures of disease activity. The incidence of adverse 
events was similar between the three groups. The same doses 
were compared further in a 12-week randomized clinical 
trial that assessed patient-reported outcomes in 356 AS 
patients.19 Treatment with etanercept 50 mg once weekly or 
25 mg twice weekly significantly improved quality of life 
and functional status compared with placebo. These studies 
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indicate that both doses of etanercept have comparable levels 
of efficacy in AS.
In 2011, ASCEND (an open-label, multicentre, supple-
mentary extension study of etanercept in subjects with anky-
losing spondylitis) compared the efficacy of etanercept and 
sulfasalazine in 566 biologic-naïve AS patients.20 Because 
the patients included had to be candidates for treatment with 
sulfasalazine, most had peripheral arthritis (70% in the etan-
ercept group and 74% in the sulfasalazine group), and some 
had already tried DMARDs (28% in both groups). Patients 
were randomized to receive etanercept 50 mg once weekly or 
sulfasalazine (maximum 3 g/day) for 16 weeks. The propor-
tion of ASAS 20 responders was significantly greater in the 
etanercept group as compared with the sulfasalazine group 
(76% versus 53%, P , 0.0001).
Finally, a recent meta-analysis that included 1,570 par-
ticipants has investigated the efficacy of etanercept in  Caucasian 
versus Chinese populations.21 Nine of the 14 randomized 
clinical trials included the ASAS 20 criteria, which was 
achieved by 72% of patients in the etanercept group versus 
28% in the placebo group (P , 0.00001), with no signifi-
cant heterogeneity between the studies. Similar results were 
found for ASAS 40, ASAS 5/6, ASAS partial remission, 
BASFI, BASDAI, BASMI, and patient global assessment. 
In addition, etanercept was effective in relieving total back 
pain, nocturnal pain, and morning stiffness, although no 
difference was found in improving chest expansion, occiput-
to-wall distance, and tender or swollen joint scores. Further, 
they found that, compared with the Chinese population, the 
Caucasian population showed higher rates of ASASA 40 and 
ASAS partial remission, and a higher incidence of treatment-
emergent adverse events.21
Comparative efficacy between  
anti-TNF therapies
The efficacy of the four anti-TNF drugs available for AS 
has not been directly compared in randomized clinical 
trials. Indirect comparisons are limited and do not show 
a significant difference in effectiveness between them.22 
Survival rates extracted from national registries have been 
used as a surrogate marker of efficacy, but controversial 
results have been reported. Data from the Austrian national 
register show better 2-year survival rates with etanercept 
than with adalimumab or infliximab,23 while the Danish 
national register shows no statistically significant differ-
ences between the three drugs.24 Overall drug survival for 
patients with rheumatoid arthritis, psoriatic arthritis, or AS 
was better for etanercept than for infliximab or adalimumab 
in the Norwegian registry,25 but this difference no longer 
exists when analyzing only first anti-TNF treatments. In 
the Czech registry,26 there were no differences in survival 
rates between the anti-TNF agents, although the difference 
between etanercept and infliximab was near statistical 
significance (P = 0.057). In addition, they found a higher 
proportion of patients with BASDAI , 4 in the etanercept 
group than in the infliximab group.
Efficacy as second-line anti-TNF therapy
Although biologic therapy can provide rapid improvement in 
AS symptoms, some patients may not respond to their first 
anti-TNF drug and other patients may worsen over time. This 
observation, along with treatment withdrawal due to adverse 
events, makes switching between anti-TNF drugs common in 
everyday clinical practice. Efficacy on switching to a second 
anti-TNF drug has been evaluated in observational studies, 
with good response rates.27
Few studies have assessed the efficacy of etanercept in 
patients who have failed to respond to previous biologic 
therapy. Switching from infliximab to etanercept has been 
evaluated in two observational studies, and reported good 
clinical response rates.28,29
Efficacy in axial spondyloarthritis  
without radiographically defined 
sacroiliitis
Recently, new ASAS classification criteria for axial spon-
dyloarthritis have been published, covering both patients 
with and without radiographic sacroiliitis.30 ABILITY (A 
Multicenter Study of the Efficacy and Safety of the Human 
Anti-TNF Monoclonal Antibody Adalimumab in Subjects 
With Axial Spondyloarthritis) demonstrated the efficacy of 
adalimumab in reducing disease activity in these patients,31 
and before these criteria were ready infliximab also demon-
strated good clinical efficacy in AS patients without radio-
graphic sacroiliitis.32
The efficacy of etanercept in patients with preradio-
graphic AS that fulfilled ASAS axial criteria was assessed 
in the ESTHER (effects of etanercept versus sulfasalazine in 
early axial spondyloarthritis on active inflammatory lesions 
as detected by whole-body magnetic resonance imaging) 
trial comparing etanercept with sulfasalazine.33 At week 48, 
reduction of edema in the sacroiliac joint on whole-body 
MRI was significantly greater in the etanercept group than in 
the sulfasalazine group. In addition, there was a reduction in 
most clinical variables, and 50% of patients in the etanercept 
group reached clinical remission.
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Another randomized clinical trial with ASAS axial 
patients, that has not yet been published, found a better 
ASAS 40 response in the etanercept group versus placebo 
(32.4% versus 15.7%, P , 0.01).34
Efficacy in severe long-standing disease
The effect of etanercept in long-standing active AS was 
analyzed in a multicenter, 12-week, randomized clinical 
trial with 82 anti-TNF-naïve patients. The patients had to 
have radiologic intervertebral bridges or spine fusion and a 
BASDAI . 4. This study reported greater improvement on 
BASDAI (area under the curve between baseline and week 
12) in the etanercept group (−19.8 ± 16.5 versus −11.0 ± 16.4, 
P = 0.019).35 In a 12-week, open-label extension of the trial, 
a significant decrease in nonsteroidal anti-inflammatory drug 
intake was found in the etanercept group.36
Efficacy in hip lesions, peripheral joints, 
and extra-articular manifestations
As previously noted, the most frequent clinical features of 
AS are sacroiliitis, enthesitis, iritis, oligoarthritis, psoriasis, 
and inflammatory bowel disease. The efficacy of etanercept 
in enthesitis was demonstrated by the ESTHER trial in 
patients with preradiographic AS on the basis of reduction of 
bone marrow edema on MRI at 27 enthesitic sites, including 
facet joints, costovertebral joints, and spinous processes.33 
 Etanercept is efficacious in the treatment of psoriasis37 and 
psoriatic arthritis,38,39 but no benefit was observed in the treat-
ment of inflammatory bowel disease.40 In a recent randomized 
clinical trial, etanercept was more effective than sulfasalazine 
in reducing the number of swollen joints in AS patients.41 In 
one observational study, etanercept was able to alleviate hip 
symptoms in patients who had not responded to conventional 
therapy.42 The efficacy of etanercept in preventing flare-up of 
anterior uveitis is reviewed elsewhere in this article.
Reduction of inflammation on MRI  
and radiographic progression
Reduction of inflammation in AS patients by etanercept is also 
confirmed as regression of bone edema assessed by spinal 
MRI.43,44 Nevertheless, radiographic progression has been 
analyzed in several trials with controversial results. Most of the 
studies that evaluated radiographic progression used the modi-
fied Stoke Ankylosing Spondylitis Spine Score (mSASSS) 
method.45 In a previously discussed trial, most patients had 
no radiographic progression using the mSASSS method at 
60 weeks.17 However, in another 2-year randomized clinical 
trial, no differences in radiographic progression were found 
when comparing etanercept-treated patients with an anti-TNF-
naïve cohort.3 Similarly negative findings were obtained with 
infliximab46 and adalimumab,47 leading to the suggestion that 
structural progression in AS is independent of TNF.
High-dose efficacy
In 2011, a 12-week, randomized clinical trial evaluated 
the efficacy of etanercept 50 mg once weekly versus twice 
weekly in 108 AS patients who had previously failed stan-
dard therapies. No significant differences were found in any 
efficacy endpoint between the treatment groups.48
Dose-tapering, extending intervals,  
or drug discontinuation
Biologic drugs are an expensive therapy and a heavy eco-
nomic burden for health care systems in many countries. 
Dose-tapering, extending intervals of administration, and 
drug discontinuation in patients in clinical remission are 
currently common practices with biologic therapy since they 
serve to curb health care costs. The efficacy of these practices 
has been assessed in several open-label studies.
Dose-tapering and interruption of etanercept was ana-
lyzed in a prospective uncontrolled trial with active AS 
biologic-naïve Korean patients.49 Treatment with etanercept 
50 mg once weekly was given for 3 months, and the dose 
was then tapered to 25 mg once a week for 6 months, and 
finally discontinued. In the first 3 months, four (14.8%) of 
27 patients dropped out because of lack of response, and one 
patient relapsed and five patients were lost to follow-up on 
25 mg maintenance therapy. After discontinuation, 67% of 
patients relapsed within 9 weeks.
In the aforementioned ESTHER trial, 8% of patients with 
axial spondyloarthritis treated with etanercept for one year 
remained in permanent drug-free remission during the year 
versus 3% of patients in the sulfasalazine group, but this 
difference was not statistically significant.50 The efficacy of 
readministration of etanercept after treatment discontinua-
tion was assessed in a previously discussed study with good 
results.13 Extending dosing intervals was assessed by another 
retrospective Korean analysis of 109 AS patients treated with 
etanercept.51 Patients started etanercept 25 mg twice weekly 
and the dosing interval gradually increased to 4.7 ± 2.1 
days at 3 months, 8.5 ± 4.9 days at 9 months, 9.9 ± 5.8 days 
at 15 months, and 12.1 ± 7.0 days at 21 months. BASDAI 
decreased from 8.5 to 0.6 at 21 months.
A very recent randomized prospective study evaluated 
the proportion of patients with AS maintaining clinical remis-
sion after extending etanercept 50 mg administration to every 
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other week.52 Patients were randomized 1:1 to a standard 
once-weekly or an extended dose. At the end of an average 
follow-up of 21 weeks, the rate of remission maintained was 
90% and 86%, respectively, with no statistically significant 
difference between the two regimens.
Finally, in an observational study in routine clinical 
practice, the etanercept dose was reduced in 16 AS patients 
in clinical remission, defined as BASDAI , 4 and  normal 
C-reactive protein levels.53 Different patterns of dose reduc-
tion were used: 25 mg weekly in four patients (25%), 25 mg 
every 10 days in one patient (6.3%), 25 mg every other week 
in two patients, 50 mg every 8 days in three patients (18.7%), 
and 50 mg every 10 days in the remaining six patients 
(37.5%). All patients remained on the low-dose regimen after 
a mean follow-up of 21 ± 21 months.
intra-articular etanercept
Promising results were obtained in 16 Chinese AS patients 
receiving computed tomography-guided intra-articular injec-
tions of etanercept 25 mg at 0, 4, and 8 weeks.54 The long-
term efficacy of this new route of administration remains to 
be demonstrated.
work disability
The effectiveness of etanercept in preventing work disabil-
ity as a result of AS was assessed in a small, double-blind, 
placebo-controlled, 12-week trial with 40 patients using the 
Ankylosing Spondylitis Work Instability Scale.55  Differences 
between groups were not statistically significant, probably due 
to the high rate of long-standing disease and the short duration 
of the study. However, in another study, etanercept showed 
improvement in work productivity among AS patients, with 
an increase in the full-time employment rate of 6.8% and a 
decrease in mean number of sick days to 22 days.56 Similar 
results were found with other anti-TNF drugs,57 so that the 
effect of these agents on work participation in real life should 
be examined further in larger population-controlled studies.
Safety of etanercept in AS
There are some differences between etanercept and other 
TNF-α blockers in terms of their mechanism of action. 
Etanercept does not induce apoptosis in some tissues (eg, the 
gastrointestinal mucosa), while both anti-TNF-α soluble 
receptor and monoclonal antibodies seem to cause apoptosis 
in the synovium.58 In contrast with adalimumab or infliximab, 
etanercept does not activate complement-dependent cytolysis 
or antibody-dependent cell-mediated cytotoxicity. In fact, 
etanercept contains the Fc portion of immunoglobulin G1, 
but does not fix the complement.58 The hypothesis of differ-
ent steric accessibility of the Fc region of etanercept could 
explain the markedly shorter plasma half-life of etanercept 
versus monoclonal antibodies.59 The above-reported find-
ings could explain some differences in the safety profile of 
etanercept with respect to infliximab and adalimumab.
Main adverse events
Data on the safety of etanercept in AS come mainly from ran-
domized clinical trials, observational open-label extensions 
of randomized clinical trials, registers, and case reports. The 
highest level of evidence is provided by randomized clinical 
trials and their meta-analyses, but it is important to remember 
that the populations included in randomized clinical trials 
are biased by their selection criteria and could be different 
in actual clinical practice. The main adverse events recorded 
during randomized clinical trials and two open-label exten-
sions in patients with AS are summarized in Table 2.
In the randomized clinical trials, the rate of adverse 
events was similar between the treatment and placebo 
groups, except for injection site reactions, which were more 
frequent in the etanercept groups.14,15,17,18 In the open-label 
Table 2 Main adverse events occurring during treatment with etanercept in patients with ankylosing spondyloarthritis in randomized 
clinical trials and open-label extensions
Adverse event AS-RCT14 AS-RCT18 AS-OLE47 AS-OLE15 AS-OLE17
ETN  
(n = 138)
PL  
(n = 139)
ETN  
(n = 151)
PL  
(n = 51)
ETN TW  
(n = 54)
ETN OW 
(n = 54)
ETN  
(n = 257)
ETN  
(n = 81)
injection site reactions 30% 9% 23% 12% 7% 8% 22% 37%
Upper respiratory tract infection 20% 12% 8% 14% 5% 8% 45% 53%
Headache 14% 12% 4% 0% ,3% ,3% 20% 20%
Diarrhea 8% 9% 4% 0% ,3% ,3% 18% 15%
Rhinitis 6% 6% ,3% ,3% ,3% ,3% NA 14%
Rash 8% 6% ,3% ,3% ,3% ,3% NA NA
Note: Adapted with permission from D’Angelo S, Palazzi C, Cantini F, Lubrano e, Marchesoni A, Mathieu A. etanercept in spondyloarthopathies. Part ii: safety and 
pharmacoeco nomic issues. Clin Exp Rheumatol. 2011;29:865–870.89
Abbreviations: AS, ankylosing spondylitis; RCT, randomized clinical trials; OLe, open-label extension; eTN, etanercept; PL, placebo; Tw, twice a week; Ow, once a week.
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extensions,15,17,47 the number of etanercept discontinuations 
because of adverse events was very low. Overall, serious 
adverse events occurred in less than 5% of the patients, and 
were often  unrelated to treatment. These results are similar to 
those reported for other anti-TNF agents in the treatment of 
AS. However, further studies are needed to compare safety 
outcomes, especially with respect to long-term follow-up.60
The safety of treatment with etanercept in patients with 
AS at high doses (100 mg per week) was compared with that 
of a standard dose (50 mg weekly) in LOADET (A 12-week 
Randomized, Double-blind, Multicenter Pilot Study to Evalu-
ate the Effect of Etanercept 100 mg and 50 mg Weekly in 
Subjects With Ankylosing Spondylitis). Adult patients with 
AS were randomized to receive etanercept 50 mg twice a 
week or etanercept 50 mg once a week for 12 weeks. They 
concluded that high-dose etanercept in the treatment of AS 
for 12 weeks is as safe as the standard dose.48
In a recent open-label extension involving 59 AS patients 
treated with etanercept for 264 weeks (original etanercept 
group) or 252 weeks (original placebo group), serious infec-
tions occurred at a rate of 0.03 events per subject years, 
while no cases of tuberculosis or opportunistic infections 
were reported.61
National registry data
Post-marketing surveillance and registers are an interesting 
source of safety data for unselected patient populations. 
The Spanish register of biologics, BIOBADASER, included 
1,524 patients with spondyloarthritis, of whom 657 had AS.62 
Most of the patients were on infliximab but there was an expo-
sure to etanercept of 134 patient-years for AS. At 3 years, 
the drug survival rate for all of the three anti-TNF-α agents 
was 0.76 for AS and 0.73 for psoriatic arthritis, with adverse 
events responsible for 45.4% of therapy  discontinuations. 
The adverse event incidence rate per 100 patient-years of 
exposure in all of the 507 patients with spondyloarthritis 
treated with etanercept was less than 1.0, with the exception 
of the infection rate, which was only 1.01.
A Norwegian register of DMARD and biologic therapy 
prescriptions collected 249 patients with AS (among other 
diseases) receiving a TNF-α antagonist. For 122 of these 
patients, etanercept was the first biologic.25 The one-year 
withdrawal rate for this drug was 24.6%. Adverse events 
were responsible for 69.2% and 43.6% of discontinua-
tions of anti-TNF-α agents in psoriatic arthritis and AS, 
respectively.
Our group conducted an observational study comparing 
the duration of treatment with etanercept with that of the rest 
of the biologic drugs in our cohort of patients on biologic 
therapy.63 We included 205 patients on biologic treatment, 
92 patients on treatment with etanercept, 33% of whom 
had AS. Adverse events as a cause of discontinuation of 
etanercept occurred in 15 patients (16%).
In conclusion, the data from existing registers seem to 
indicate that in standard clinical settings of patients with AS, 
anti-TNF-α agents, and etanercept in particular, are more 
often responsible for drug discontinuation than in random-
ized clinical trials but, nevertheless, these molecules have a 
good safety profile.
Reactivation of tuberculosis, reactivation of hepatitis B 
virus infection, congestive heart failure, demyelinating neu-
rologic disorders, hematologic disorders like aplastic anemia 
or pancytopenia, vasculitis, immunogenicity, and exacerba-
tion or induction of psoriasis are class effects seen with all 
of the TNF-α inhibitors, and have been seen in patients with 
rheumatoid arthritis and those with spondyloarthritis.64,65
Reactivation of tuberculosis
The number of tuberculosis cases decreased after institu-
tion of tuberculosis screening, but the problem has not dis-
appeared completely. Since the screening test may produce 
false negative results and first infection during etanercept 
treatment may occur, careful vigilance and repeat screening 
for tuberculosis has been suggested.66 It has been confirmed 
that etanercept is less likely to reactivate tuberculosis than 
the other TNF-α antagonists.67,68 In addition, etanercept did 
not induce any reactivation of tuberculosis in a cohort of 
84 patients, including those with AS or psoriatic arthritis 
or those at high risk for tuberculosis infections (purified 
protein derivative-positive patients).69 An interesting point 
is the relationship between TNF-α blockers and produc-
tion of interferon-γ. In fact, interferon-γ expression was 
inhibited by infliximab, but not by etanercept,70,71 suggest-
ing that the risk of granuloma-dependent infection may 
reflect an ability to inhibit both TNF-α and (indirectly) 
interferon-γ.58
Hepatitis B virus, hepatitis C virus,  
and human immunodeficiency virus
Reactivation of hepatitis B virus, congestive heart failure, 
and demyelinating diseases are potential adverse events of 
anti-TNF-α therapy that can occur regardless of the under-
lying condition. Vasculitis is much more likely to occur 
in patients with rheumatoid arthritis than in those with 
 spondyloarthritis.72,73 Treatment with etanercept in the setting 
of chronic hepatitis C virus infection seems to be safe, but 
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the relevant data are obtained mainly from studies of patients 
with rheumatoid arthritis.64,74
The safety of etanercept in human immunodeficiency 
virus (HIV)-positive patients has also been studied. There are 
published retrospective series of HIV-positive patients with 
rheumatoid arthritis, spondyloarthritis, or psoriasis treated 
with anti-TNF drugs (including etanercept). These studies 
suggest that treatment with anti-TNF-α therapy is a viable 
alternative for HIV patients without advanced disease but 
with associated rheumatic diseases refractory to standard 
therapy.75,76
immunogenicity
It has been suggested that etanercept might be less 
 immunogenic than the other TNF-α antagonists,  especially 
in AS.73,77 Immunogenicity, specifically the onset of antibod-
ies against TNF-blocking agents, seems to play an important 
role in lack of response to treatment with these drugs.78 
Some studies in patients with rheumatoid arthritis have 
demonstrated that lower etanercept levels were associated 
with lack of response,79,80 and antibodies against etanercept, 
all non-neutralizing, were obtained in less than 2% of the 
patients.81 The relationship of clinical response in AS with 
etanercept levels and the presence of antibodies to etaner-
cept was recently assessed in 53 consecutive patients.77 All 
patients with AS had detectable etanercept levels, regard-
less of whether they were responders or non-responders. In 
contrast with previous studies of other TNF-blocking agents, 
no antibodies against etanercept were detected in any of the 
assays. This study indicates that immunogenicity does not 
play an important role in explaining the non-response of 
patients with AS to treatment with etanercept.77
Paradoxical psoriasis
Exacerbation or induction of psoriasis is a paradoxical effect 
of TNF-α inhibition that is not specific to AS, and has been 
reported in other diseases.65 The scientific evidence in this 
regard suggests that while the anti-TNF-α monoclonal anti-
bodies can induce new-onset psoriasis, etanercept is more 
likely to cause flare-ups of existing disease.82
Malignancy
The relationship between malignancy and anti-TNF-α drugs 
is an unresolved concern. In rheumatoid arthritis, some stud-
ies did not find an increased incidence of lymphoma or solid 
cancers in patients taking TNF-α inhibitors, while others 
did.83 In a recent systematic review, patients with psoriatic 
arthritis or psoriasis treated with anti-TNF agents showed 
increased rates of non-melanoma skin cancer.84 This risk 
was increased by treatment with methotrexate, cyclosporine, 
and phototherapy.
A recent meta-analysis of registries and a systematic 
review of long-term extension studies did not reveal an 
increased risk of malignancy in patients with rheumatoid 
arthritis receiving anti-TNF therapy.85 The pooled odds ratio 
for total malignancy and for non-melanoma skin cancers 
was 0.81 (95% confidence interval [CI] 0.71–0.94) and 0.79 
(95% CI 0.62–1.02) in an TNF-antagonist group versus a 
DMARD group, respectively. Among four long-term studies 
and four registries, no significant increase in incidence of 
total malignancy was noted versus the general population. 
Only an increased risk of non-melanoma skin cancers was 
found. The presence of many confounding factors, the low 
rate of malignancies, and the long length of time needed for 
a cancer to develop complicate the search for an answer to 
this question. Although the data on malignancy in patients 
with spondyloarthritis treated with anti-TNF agents are scant, 
the strong immunosuppressive effect of these drugs implies 
a potential risk of cancer.
Acute uveitis, Crohn’s disease,  
and sarcoidosis
Acute uveitis, Crohn’s disease, and sarcoidosis are other 
adverse events that have been rarely associated with etaner-
cept therapy in AS patients. Several anecdotal reports and a 
study using observations from two drug event databases have 
suggested that etanercept may be responsible for flare-ups or 
new occurrences of acute anterior uveitis.86 In contrast, other 
data have shown that etanercept may prevent acute uveitis in 
AS, although less effectively than infliximab.87
In this regard, a systematic review of the literature was 
recently conducted in order to analyze the effectiveness of 
immunosuppressants and biologic therapies in patients with 
autoimmune posterior uveitis, chronic anterior uveitis associ-
ated with juvenile idiopathic arthritis, and macular edema. 
The authors concluded that biologic therapies (except for 
etanercept and daclizumab in Behcet’s disease) are beneficial 
for the treatment of autoimmune uveitis. They did not con-
sider etanercept to be as effective in autoimmune uveitis, as 
per recommendation A, evidence level 1b.88 Therefore, con-
sidering all the available data, it seems likely that etanercept 
is not as effective as the anti-TNF-α monoclonal antibodies 
in treating and preventing acute uveitis.89
Unlike the other two TNF-α inhibitors, etanercept is not 
effective in controlling active Crohn’s disease.40 In fact, new-
onset Crohn’s disease has been described in AS patients with 
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etanercept.90 Crohn’s disease may be considered an immune-
mediated injury induced by etanercept, but the causative role 
of etanercept has not been demonstrated at this point.
Paradoxical development of sarcoidosis in patients 
on etanercept therapy has been reported in patients with 
spondyloarthritis.87,91,92
Geriatric patients
An interesting issue regarding the safety profile of etanercept 
therapy is its use in geriatric patients, who may be more prone 
to develop adverse events. However, elderly patients are usu-
ally excluded from randomized clinical trials. A retrospective 
analysis of trials with etanercept in rheumatoid arthritis, AS, 
and psoriatic arthritis, has shown that for patients $65 years, 
the rate of adverse events and serious adverse events was not 
higher than for younger patients.93
Pregnancy
Neither animal studies nor prospective, controlled human 
studies have shown an increased rate of adverse outcomes 
after exposure to etanercept during pregnancy.94  Nevertheless, 
their use during pregnancy is still controversial, because it 
remains unclear whether the benefits of treatment might be 
outweighed by potential teratogenicity or adverse effects on 
the course of pregnancy. Based on the available literature, 
experts suggest that continuation of treatment with TNF-α 
blockers is justified in pregnant patients with high disease 
activity and disease progression.95–97
Fertility and breast-feeding
There are scarce data in the literature in regard to fertility in 
AS patients treated with etanercept, but we can find indirect 
evidence from some studies. The effect of TNF-α and TNF-α 
antagonists on semen quality in men is controversial. One 
study reported that infliximab infusion did not affect semen 
volume, sperm concentration, or forward progression, but 
that it did decrease sperm motility and the percentage of 
normal oval forms.98 However, in another study done with 
sperm suspensions incubated with different doses of TNF-α, 
TNF-α plus infliximab, and infliximab alone, sperm motility 
and membrane integrity were higher in the samples incubated 
with TNF-α plus infliximab than in the samples treated with 
TNF-α or infliximab alone. This study demonstrates that 
exposing spermatozoa to increased concentrations of TNF-α 
results in a loss of functional and genomic spermatozoa 
integrity and that infliximab is capable of reversing the toxic 
effects induced by TNF-α.99 Since the effects of possible 
transfer of etanercept to maternal milk in a still immature 
immune system are not known, in accordance with the risk/
benefit principle, the use of etanercept is not recommended 
in breast-feeding women.100
Conclusion
In the 12 years since commercialization of etanercept, its 
 efficacy has been confirmed in AS, as shown in randomized 
clinical trials, open-label extension studies, and national 
 registries. Etanercept is effective in different manifestations of 
the disease, including back pain, peripheral arthritis, enthesitis, 
and psoriasis. However, etanercept has shown no efficacy in 
inflammatory bowel disease, and its efficacy in the treatment 
of uveitis appears to be lower than that of the other anti-TNF 
drugs. Other aspects of AS, like radiographic progression, 
remain to be clarified in the future, since all the available 
anti-TNF agents have not shown efficacy in this regard to date. 
In the current economic crisis, etanercept has proved to be a 
useful drug, is able to maintain high rates of clinical remis-
sion when extending dosing intervals, and is efficacious when 
readministered after discontinuation of treatment. Regarding 
safety, up to 5 years of data from randomized clinical trials, 
open-label extensions, registries, and meta-analysis show that 
continuous long-term treatment with etanercept has a favorable 
risk-benefit ratio and no cumulative toxicity.
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